DPT has signed an agreement to acquire a manufacturing facility owned by Meda in Lakewood, NJ. The site is dedicated to global supply of the product MUSE, a urethral suppository for the treatment of erectile dysfunction. As part of the agreement Meda has entered into a long-term supply agreement with DPT for MUSE. Financial terms were not disclosed.
The acquisition reflects DPT’s recent growth, allowing the company to expand its footprint in Lakewood by adding two buildings totaling 90,000 square feet of space. The real estate meets the organization’s current need for additional cold storage and a larger state-of-the-art analytical laboratory.
“The Meda Pharmaceuticals space allows us to meet the needs of our clients today and beyond,” said Gene Ciolfi, vice president and general manager, Lakewood site operations. “We are also in a better position to explore additional opportunities to further our capabilities from development through commercialization.
“We look forward to transitioning Meda Pharmaceuticals’ personnel to the DPT team,” he added. “Their experience and continued dedication to quality complements our commitment to outstanding client service.”
DPT’s current Lakewood location is one of the organization’s established Centers of Excellence. This center provides state-of-the-art aseptic processing suites and filling equipment for small-volume parenterals, ophthalmic preparations, preservative-free nasal sprays and sterile ointments.
DPT is a General Member of the Pharma & Biopharma Outsourcing Association. Visit our Benefits page to learn more about the PBOA.
